LINCOLN, Neb., April 28, 2025--(BUSINESS WIRE)--National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments.
Highlights:
Overview
Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company’s performance and recent developments:
"The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of our sales force - never a quick process, but one that is already delivering results. We are seeing meaningful increases in our pipeline, win rates, and overall sales. Building on this momentum, we are now aggressively accelerating our sales force expansion plans to fully capitalize on our broader product offerings and a differentiated message that sets NRC Health apart in the marketplace."
Hays continued, "I would also like to recognize Helen Hrdy, our Chief Operating Officer, for her relentless focus on driving organizational efficiencies. Her leadership continues to be instrumental in enhancing our ability to invest in future growth while delivering strong returns to shareholders through share repurchases and dividends."
Hays concluded, "Finally, I welcome the opportunity to personally introduce you to Trent Green, who will be joining us as our incoming CEO in June. Introductory calls are available on June 9 and 10, 2025 and can be arranged by contacting MBachman@NRCHealth.com."
Dividends and Share Repurchase
The Company’s Board of Directors on April 25, 2025, declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, July 11, 2025, to shareholders of record as of the close of business on Friday, June 27, 2025.
During the first quarter, the Company completed its prior share repurchase program adopted in 2022. On April 25, 2025, the Company’s Board of Directors approved repurchasing up to one million additional shares of its common stock.
About NRC Health
For more than 40 years, NRC Health’s (NASDAQ: NRC) commitment to Human Understanding® helps leading healthcare systems know each patient, caregivers, employees, and the communities they serve not as point-in-time insights, but to personalize an ongoing relationship at scale. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as "believes," "expect," "focus," "potential," "will," derivations thereof, and similar terms and phrases. In this press release, the statements related to future dividends, share repurchases, and revenue are forward-looking statements. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY |
|||||||
Three months ended March 31, |
|||||||
2025 |
2024 |
||||||
Revenue |
$ |
33,551 |
$ |
35,313 |
|||
Operating expenses: |
|||||||
Direct |
13,057 |
13,856 |
|||||
Selling, general and administrative |
10,356 |
11,250 |
|||||
Depreciation and amortization |
1,542 |
1,447 |
|||||
Total operating expenses |
24,955 |
26,553 |
|||||
Operating income |
8,596 |
8,706 |
|||||
Other income (expense): |
|||||||
Interest income |
19 |
44 |
|||||
Interest expense |
(899 |
) |
(605 |
) |
|||
Other, net |
7 |
(5 |
) |
||||
Total other income (expense) |
(873 |
) |
(566 |
) |
|||
Income before income taxes |
7,723 |
8,194 |
|||||
Provision for income taxes |
1,936 |
1,835 |
|||||
Net income |
$ |
5,787 |
$ |
6,359 |
|||
Earnings Per Share of Common Stock: |
|||||||
Basic Earnings Per Share |
$ |
0.25 |
$ |
0.27 |
|||
Diluted Earnings Per Share |
$ |
0.25 |
$ |
0.27 |
|||
Weighted average shares and share equivalents outstanding |
|||||||
Basic |
22,972 |
23,868 |
|||||
Diluted |
22,974 |
23,963 |
|||||
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY |
||||||||
March 31, 2025 |
December 31, 2024 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ |
2,502 |
$ |
4,233 |
||||
Accounts receivable, net |
11,326 |
11,054 |
||||||
Other current assets |
6,574 |
4,313 |
||||||
Total current assets |
20,402 |
19,600 |
||||||
Property and equipment, net |
40,390 |
38,269 |
||||||
Goodwill |
66,152 |
66,152 |
||||||
Other, net |
8,231 |
8,518 |
||||||
Total assets |
$ |
135,175 |
$ |
132,539 |
||||
Liabilities and Shareholders’ Equity |
||||||||
Current liabilities: |
||||||||
Current portion of notes payable, net of unamortized debt issuance costs |
$ |
3,036 |
$ |
4,789 |
||||
Line of credit |
3,500 |
-- |
||||||
Accounts payable and accrued expenses |
6,743 |
6,285 |
||||||
Accrued compensation |
4,915 |
4,774 |
||||||
Deferred revenue |
15,507 |
15,786 |
||||||
Dividends payable |
2,735 |
2,770 |
||||||
Other current liabilities |
1,338 |
1,454 |
||||||
Total current liabilities |
37,774 |
35,858 |
||||||
Notes payable, net of current portion and unamortized debt issuance costs |
58,669 |
57,895 |
||||||
Other non-current liabilities |
9,060 |
7,502 |
||||||
Total liabilities |
105,503 |
101,255 |
||||||
Shareholders’ equity: |
||||||||
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued |
-- |
-- |
||||||
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,082,158 in 2025 and 31,072,144 in 2024, outstanding 22,785,421 in 2025 and 23,083,116 in 2024 |
31 |
31 |
||||||
Additional paid-in capital |
180,552 |
180,249 |
||||||
Retained earnings (accumulated deficit) |
(14,012 |
) |
(17,064 |
) |
||||
Treasury stock |
(136,899 |
) |
(131,932 |
) |
||||
Total shareholders’ equity |
$ |
29,672 |
$ |
31,284 |
||||
Total liabilities and shareholders’ equity |
$ |
135,175 |
$ |
132,539 |
||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20250428584314/en/
Contacts
Michelle Bachman
402-475-2525
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.